Genetic engineering for haemophilia A

Expert Opinion on Biological Therapy

Volumn 6, Issue 10, 2006, Pages 1023-1030

  Gan, Shu Uin ^a   Kon, Oi Lian ^b   Calne, Roy Y ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cell therapy; Gene therapy; Haemophilia A; Plasmid vectors; Viral vectors

Indexed keywords

BLOOD CLOTTING FACTOR 8; PLASMID VECTOR; VIRUS VECTOR;

ANTIBODY PRODUCTION; CLINICAL TRIAL; GENE THERAPY; GENETIC ENGINEERING; HEMOPHILIA A; HUMAN; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; REVIEW; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; GENE THERAPY; GENETIC ENGINEERING; HEMOPHILIA A; HUMANS;

ANIMALIA;

EID: 33749337200     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.10.1023     Document Type: Review

References (76)

1. BI L, LAWLER AM, ANTONARAKIS SE et al.: Targeted disruption of the mouse Factor VIII gene produces a model of haemophilia A. Nat. Genet. (1995) 10(1):119-121.
2. ROTH DA, TAWA NE JR, O'BRIEN JM, TRECO DA, SELDEN RF: Nonviral transfer of the gene encoding coagulation Factor VIII in patients with severe haemophilia A. N. Engl. J. Med. (2001) 344(23):1735-1742. Clinical trial using a non-viral vector.
3. POWELL JS, RAGNI MV, WHITE GC 2ND et al.: Phase I trial of FVIII gene transfer for severe haemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood (2003) 102(6):2038-2045. Clinical trial using a retroviral vector.
4. PITTMAN DD, ALDERMAN EM, TOMKINSON KN et al.: Biochemical, immunological, and in vivo functional characterization of B-domain-deleted Factor VIII. Blood (1993) 81(11):2925-2935.
5. MIAO HZ, SIRACHAINAN N, PALMER L et al.: Bioengineering of coagulation Factor VIII for improved secretion. Blood (2004) 103(9):3412-3419.
6. KANG Y, XIE L, TRAN DT et al.: Persistent expression of Factor VIII in vivo following nonprimate lentiviral gene transfer. Blood (2005) 106(5):1552-1558.
7. KAUFMAN RJ, PIPE SW, TAGLIAVACCA L, SWAROOP M, MOUSSALLI M: Biosynthesis, assembly and secretion of coagulation Factor VIII. Blood Coagul. Fibrinolysis (1997) 8(Suppl. 2):S3-S14.
8. HOLLESTELLE MJ, THINNES T, GRAIN K et al.: Tissue distribution of Factor VIII gene expression in vivo-a closer look. Thromb. Haemost. (2001) 86(3):855-861.
9. LONG YC, JAICHANDRAN S, HO LP et al.: FVIII gene delivery by muscle electroporation corrects murine haemophilia A. J. Gene Med. (2005) 7(4):494-505.
10. YE P, THOMPSON AR, SARKAR R et al.: Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in haemophilia A mice. Mol. Ther. (2004) 10(1):117-126.
11. AL-DOSARI MS, KNAPP JE, LIU D: Hydrodynamic delivery. Adv. Genet. (2005) 54:65-82.
12. MEI WH, QIAN GQ, ZHANG XQ, ZHANG P, LU J: Sustained expression of Epstein-Barr virus episomal vector mediated Factor VIII in vivo following muscle electroporation. Haemophilia (2006) 12(3):271-279.
13. CONESE M, AURICHE C, ASCENZIONI F: Gene therapy progress and prospects: episomally maintained self-replicating systems. Gene Ther. (2004) 11(24):1735-1741.
14. TSIMBOURI P, DROTAR ME, COY JL, WILSON JB: bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene (2002) 21(33):5182-5187.
15. OHLFEST JR, FRANDSEN JL, FRITZ S et al.: Phenotypic correction and long-term expression of Factor VIII in haemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood (2005) 105(7):2691-2698. A combination of tolerising neonatal haemophilia A mice with transposon plasmid vector carrying FVIII results in long-term FVIII expression without inhibitor formation.
16. OHLFEST JR, LOBITZ PD, PERKINSON SG, LARGAESPADA DA: Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system. Mol. Ther. (2004) 10(2):260-268.
17. LIU L, MAH C, FLETCHER BS: Sustained FVIII expression and phenotypic correction of haemophilia A in neonatal mice using an endothelial-targeted Sleeping Beauty transposon. Mol. Ther. (2006) 13(5):1006-1115.
18. CHEN ZY, HE CY, EHRHARDT A, KAY MA: Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol. Ther. (2003) 8(3):495-500.
19. EHRHARDT A, XU H, HUANG Z, ENGLER JA, KAY MA: A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. Mol. Ther. (2005) 11(5):695-706.
20. CHAO H, MANSFIELD SG, BARTEL RC et al.: Phenotype correction of haemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat. Med. (2003) 9(8):1015-1019. An alternative method of mRNA repair to treat haemophilia A mice, resulting in long-term phenotypic correction.
21. SARKAR R, TETREAULT R, GAO G et al.: Total correction of haemophilia A mice with canine FVIII using an AAV 8 serotype. Blood (2004) 103(4):1253-1260.
22. SARKAR R, XIAO W, KAZAZIAN HH JR: A single adeno-associated virus (AAV)-murine Factor VIII vector partially corrects the haemophilia A phenotype. J. Thromb. Haemost. (2003) 1(2):220-226.
23. ISHIWATA A, MIMURO J, KASHIWAKURA Y et al.: Phenotype correction of haemophilia A mice with adeno-associated virus vectors carrying the B domain-deleted canine Factor VIII gene. Thromb. Res. (2005) (In Press).
24. SARKAR R, MUCCI M, ADDYA S et al.: Long-term efficacy of adeno-associated virus serotypes 8 and 9 in haemophilia A dogs and mice. Hum. Gene Ther. (2006) 17(4):427-439.
25. SCALLAN CD, LILLICRAP D, JIANG H et al.: Sustained phenotypic correction of canine haemophilia A using an adeno-associated viral vector. Blood (2003) 102(6):2031-2037.
26. SCALLAN CD, LIU T, PARKER AE et al.: Phenotypic correction of a mouse model of haemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood (2003) 102(12):3919-3926.
27. JIANG H, LILLICRAP D, PATARROYO-WHITE S et al.: Multi-year therapeutic benefit of AAV serotypes 2, 6 and 8 delivering Factor VIII to haemophilia A mice and dogs. Blood (2006) 108(1):107-115. An average of 2 - 4% of normal levels of cFVIII persisted for > 3 years in treated dogs.
28. VANDENDRIESSCHE T, THORREZ L, NALDINI L et al.: Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood (2002) 100(3):813-822.
29. SANDRIN V, RUSSELL SJ, COSSET FL: Targeting retroviral and lentiviral vectors. Curr. Top. Microbiol. Immunol. (2003) 281:137-178.
30. VERHOEYEN E, COSSET FL: Surface-engineering of lentiviral vectors. J. Gene Med. (2004) 6(Suppl. 1):S83-S94.
31. XU L, NICHOLS TC, SARKAR R et al.: Absence of a desmopressin response after therapeutic expression of Factor VIII in haemophilia A dogs with liver-directed neonatal gene therapy. Proc. Natl. Acad. Sci. USA (2005) 102(17):6080-6085. Neonatal gene therapy with a retroviral vector carrying cFVIII resulted in therapeutic levels of cFVIII in haemophila A mice and dogs for 1.5 years. No notable inhibitor formation was observed.
32. XU L, O'MALLEY T, SANDS MS et al.: In vivo transduction of haematopoietic stem cells after neonatal intravenous injection of an amphotropic retroviral vector in mice. Mol. Ther. (2004) 10(1):37-44.
33. XU L, GAO C, SANDS MS et al.: Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine Factor IX for haemophiliaB. Blood (2003) 101(10):3924-3932.
34. VANDENDRIESSCHE T, VANSLEMBROUCK V, GOOVAERTS I et al.: Long-term expression of human coagulation Factor VIII and correction of haemophilia A after in vivo retroviral gene transfer in Factor VIII-deficient mice. Proc. Natl. Acad. Sci. USA (1999) 96(18):10379-10384.
35. GALLO-PENN AM, SHIRLEY PS, ANDREWS JL et al.: Systemic delivery of an adenoviral vector encoding canine Factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in haemophilia A dogs. Blood (2001) 97(1):107-113.
36. BROWN BD, SHI CX, POWELL S et al.: Helper-dependent adenoviral vectors mediate therapeutic Factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe haemophilia A. Blood (2004) 103(3):804-810.
37. PARK F: Correction of bleeding diathesis without liver toxicity using arenaviral-pseudotyped HIV-1-based vectors in haemophilia A mice. Hum. Gene Ther. (2003) 14(15):1489-1494.
38. KOOTSTRA NA, MATSUMURA R, VERMA IM: Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol. Ther. (2003) 7(5 Pt 1):623-631.
39. STEIN CS, KANG Y, SAUTER SL et al.: In vivo treatment of haemophilia A and mucopolysaccharidosis Type VII using nonprimate lentiviral vectors. Mol. Ther. (2001) 3(6):850-856.
40. OGATA K, MIMURO J, KIKUCHI J et al.: Expression of human coagulation Factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for haemophilia A gene therapy. Gene Ther. (2004) 11(3):253-259.
41. PARK F, OHASHI K, KAY MA: Therapeutic levels of human Factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood (2000) 96(3):1173-1176.
42. RAWLE FE, SHI CX, BROWN B et al.: Heterogeneity of the immune response to adenovirus-mediated Factor VIII gene therapy in different inbred hemophilic mouse strains. J. Gene Med. (2004) 6(12):1358-1368.
43. CHUAH MK, SCHIEDNER G, THORREZ L et al.: Therapeutic Factor VIII levels and negligible toxicity in mouse and dog models of haemophilia A following gene therapy with high-capacity adenoviral vectors. Blood (2003) 101(5):1734-1743.
44. MURUVE DA: The innate immune response to adenovirus vectors. Hum. Gene Ther. (2004) 15(12):1157-1166.
45. LIPSHUTZ GS, SARKAR R, FLEBBE-REHWALDT L, KAZAZIAN H, GAENSLER KM: Short-term correction of Factor VIII deficiency in a murine model of haemophilia A after delivery of adenovirus murine Factor VIII in utero. Proc. Natl. Acad. Sci. USA (1999) 96(23):13324-13329.
46. O'NEAL WK, ZHOU H, MORRAL N et al.: Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector. Mol. Med. (2000) 6(3):179-195.
47. ANDREWS JL, KADAN MJ, GORZIGLIA MI, KALEKO M, CONNELLY S: Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human Factor VIII. Mol. Ther. (2001) 3(3):329-336.
48. BALAGUE C, ZHOU J, DAI Y et al.: Sustained high-level expression of full-length human Factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood (2000) 95(3):820-828.
49. ZHANG WW, JOSEPHS SF, ZHOU J et al.: Development and application of a minimal-adenoviral vector system for gene therapy of haemophilia A. Thromb. Haemost. (1999) 82(2):562-571.
50. BROWN BD, SHI CX, RAWLE FE et al.: Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in haemophilia A mice. J. Thromb. Haemost. (2004) 2(1):111-118.
51. GNATENKO DV, WU Y, JESTY J et al.: Expression of therapeutic levels of Factor VIII in A mice using a novel adeno/adeno-associated hybrid virus. Thromb. Haemost. (2004) 92(2):317-327.
52. GARCIA-MARTIN C, CHUAH MK, VAN DAMME A et al.: Therapeutic levels of human Factor VIII in mice implanted with encapsulated cells: potential for gene therapy of haemophilia A. J. Gene Med. (2002) 4(2):215-223.
53. HORTELANO G, WANG L, XU N, OFOSU FA: Sustained and therapeutic delivery of Factor IX in nude haemophilia B mice by encapsulated C2C12 myoblasts: concurrent tumourigenesis. Haemophilia (2001) 7(2):207-214.
54. HOEBEN RC, FALLAUX FJ, VAN TILBURG NH et al.: Toward gene therapy for haemophilia A: long-term persistence of Factor VIII-secreting fibroblasts after transplantation into immunodeficient mice. Hum. Gene Ther. (1993) 4(2):179-186.
55. LIN Y, CHANG L, SOLOVEY A et al.: Use of blood outgrowth endothelial cells for gene therapy for haemophilia A. Blood (2002) 99(2):457-462.
56. HOEBEN RC, EINERHAND MP, BRIET E et al.: Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a Factor VIII gene into murine haematopoietic progenitor cells. Thromb. Haemost. (1992) 67(3):341-345.
57. EVANS GL, MORGAN RA: Genetic induction of immune tolerance to human clotting Factor VIII in a mouse model for haemophilia A. Proc. Natl. Acad. Sci. USA (1998) 95(10):5734-5739.
58. KIKUCHI J, MIMURO J, OGATA K et al.: Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation Factor VIII gene in NOD/SCID mice. J. Gene Med. (2004) 6(10):1049-1060.
59. TIEDE A, EDER M, VON DEPKA M et al.: Recombinant Factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Ther. (2003) 10(22):1917-1925.
60. MOAYERI M, RAMEZANI A, MORGAN RA, HAWLEY TS, HAWLEY RG: Sustained phenotypic correction of haemophilia a mice following oncoretroviral-mediated expression of a bioengineered human Factor VIII gene in long-term hematopoietic repopulating cells. Mol. Ther. (2004) 10(5):892-902.
61. CHUAH MK, BREMS H, VANSLEMBROUCK V, COLLEN D, VANDENDRIESSCHE T: Bone marrow stromal cells as targets for gene therapy of haemophilia A. Hum. Gene Ther. (1998) 9(3):353-365.
62. HERDER C, TONN T, OOSTENDORP R et al.: Sustained expansion and transgene expression of coagulation Factor VIII-transduced cord blood-derived endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. (2003) 23(12):2266-2272.
63. ANANYEVA NM, LACROIX-DESMAZES S, HAUSER CA et al.: Inhibitors in haemophilia A: mechanisms of inhibition, management and perspectives. Blood Coagul. Fibrinolysis (2004) 15(2):109-124.
64. DIMICHELE D: Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia (2002) 8(3):280-287.
65. MIAO CH, YE P, THOMPSON AR, RAWLINGS DJ, OCHS HD: Immunomodulation of transgene responses following naked DNA transfer of human Factor VIII into haemophilia A mice. Blood (2006) 108(1):19-27.
66. MADOIWA S, YAMAUCHI T, HAKAMATA Y et al.: Induction of immune tolerance by neonatal intravenous injection of human Factor VIII in murine haemophilia A. J. Thromb. Haemost. (2004) 2(5):754-762.
67. CALNE R, FRIEND P, MOFFATT S et al.: Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet (1998) 351(9117):1701-1702.
68. LE BLANC K, TAMMIK L, SUNDBERG B, HAYNESWORTH SE, RINGDEN O: Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibiltty complex. Scand. J. Immunol (2003) 57(1):11-20.
69. AGGARWAL S, PITTENGER MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood (2005) 105(4):1815-1822.
70. PUISSANT B, BARREAU C, BOURIN P et al.: Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br. J. Haematol. (2005) 129(1):118-129.
71. RYAN JM, BARRY FP, MURPHY JM, MAHON BP: Mesenchymal stem cells avoid allogeneic rejection. J. Inflamm. (London) (2005) 2:8.
72. LE BLANC K, RASMUSSON I, SUNDBERG B et al.: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet (2004) 363(9419):1439-1441.
73. LI CD, ZHANG WY, LI HL et al.: Mesenchymal stem cells derived from human placenta suppress allogeneic umbilical cord blood lymphocyte proliferation. Cell Res. (2005) 15(7):539-547.
74. LI CD, ZHANG WY, LI HL et al.: Isolation and identification of a multilineage potential mesenchymal cell from human placenta. Placenta (2005) (In Press).
75. BAILO M, SONCINI M, VERTUA E et al.: Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation (2004) 78(10):1439-1448.
76. BROXMEYER HE: Biology of cord blood cells and future prospects for enhanced clinical benefit. Cytotherapy (2005) 7(3):209-218.